Earnings call transcript: InnovAge Q3 2026 sees revenue growth, stock rise

InnovAge reported Q3 FY2026 revenue of $251.9 million, up 15.5% year over year and above the $234.5 million forecast, while adjusted EBITDA rose to $30.5 million with margin expansion to 12.1% and center-level contribution margin improving to 24.2% (+550 bps YoY). The offset was a net loss of $29.9 million, or $0.22 per share, driven in part by a large litigation-related increase in corporate G&A. Management raised full-year FY2026 guidance to $950 million-$975 million of revenue and $85 million-$90 million of adjusted EBITDA, and the stock rose 2.82% after hours.

Analysis

INNV is increasingly looking like a cash-generative operating leverage story rather than a simple top-line grower. The key second-order effect is that a higher margin base plus operating cash flow reduces the company’s dependence on favorable rate-set outcomes to fund growth, which should help the multiple if investors believe management can keep reinvesting without eroding service quality. The market is likely underappreciating how much of the “good news” is now self-reinforcing: better participant experience lowers friction/disenrollment, which supports census, which improves fixed-cost absorption, which funds more reinvestment.

The real overhang is not current-quarter profitability but the bridge to FY27, where rates may become a headwind just as management leans harder into growth investments. That creates a subtle tension: if they over-invest in sales, clinical tech, and new-center maturation while reimbursement weakens, EBITDA cadence could flatten even if revenue keeps rising. The litigation charge is more important as a signaling mechanism than as a quarter-specific item — it raises the probability that reported GAAP earnings remain noisy, which can cap re-rating unless cash conversion stays visibly strong.

Consensus seems too anchored on the idea that margin expansion must continue from here. Management’s own posture suggests the more likely regime is stable margins with higher reinvestment, not further step-function expansion; that is still constructive, but it changes what the stock can rerate on. The contrarian setup is that a modestly weaker reimbursement backdrop may actually be bullish for disciplined operators if weaker peers can’t fund the same level of care coordination and enrollment infrastructure, creating share gains for INNV over 6-12 months.

Key Decisions for Investors

• Long INNV on a 3-6 month horizon into the next guidance update: own for operating cash flow durability and potential share gains if weaker PACE operators struggle with FY27 rate pressure; risk/reward is attractive if the stock can rerate on stable EBITDA rather than expanding margins.
• Buy INNV pullbacks on any post-earnings fade below the current trading range; use a 10-15% stop as the main risk is that FY27 reimbursement commentary turns sharper than expected and compresses the multiple.
• Pair trade: long INNV / short a basket of small-cap healthcare services names with higher reimbursement sensitivity and weaker balance sheets; the thesis is INNV’s scale and cash generation should make it a relative winner if rates slow.
• If options are liquid enough, buy 3-4 month call spreads in INNV rather than outright calls; the stock’s move is likely to be grind-up rather than explosive, and call spreads better fit a modest upside re-rating scenario.
• Avoid chasing after the aftermarket pop; wait for confirmation that FY27 cost discipline holds before adding aggressively, since the next catalyst is budget/rate clarity, not another immediate earnings beat.